How do you start a med spa (medical aesthetics clinic) business in 2027?

Direct Answer

Starting a med spa (medical aesthetics clinic) business in 2027 means launching a state-licensed medical aesthetics clinic -- a hybrid retail-clinical environment delivering physician-supervised injectables, energy-based device procedures, medical-grade skincare, and adjunct wellness services.

Unlike a day spa (no medical procedures, esthetician-only) or a dermatology practice (medical-only, insurance-billing dominant), a med spa is a cash-pay, recurring-revenue, brand-driven format that sits in the highest-growth, highest-margin corner of the roughly $80B-$95B US aesthetic and cosmetic procedure market.

The build runs on three regulatory pillars that must all be solved before the doors open: (1) a medical director (MD/DO) plus state scope-of-practice rules governing who can legally inject; (2) the corporate practice of medicine (CPOM) doctrine in 30-plus states, which forces a non-physician owner into an MSO + Professional Corporation "friendly-PC" stack; and (3) good-faith exam (GFE), HIPAA, EMR, DEA, and FDA-compounding compliance, including the post-October-2024 compounded-GLP-1 enforcement reset.

Capital runs $400K-$1.5M for a solo turnkey clinic (1,500-2,500 sqft, 2-4 treatment rooms) and $1.5M-$3.5M for a multi-room flagship (3,000-5,000 sqft). Mature solo economics land at 55-70% gross margin and 15-30% net on $1.4M-$3.8M revenue; multi-room flagships run $3.5M-$9M revenue at 18-28% EBITDA.

The hardest part is not capital and not concept. It is medical-director recruiting and dependency, state injector-scope tightening, good-faith-exam telehealth rules, FDA compounded-GLP-1 enforcement, nurse-injector poaching and turnover, and the commoditization of Botox pricing by corporate chains.

Solve those, hit 25-45% membership penetration, and the unit economics of 2027 medical aesthetics are excellent.

TL;DR

• Capital: $400K-$1.5M turnkey solo med spa (1,500-2,500 sqft medical-grade buildout $250K-$650K -- procedure rooms with hand-wash sinks, lockable Rx storage, HVAC laser-plume ventilation, ADA, NEC, biohazard; opening Allergan injectables order $30K-$80K; 1-2 lasers $85K-$250K; HydraFacial $25K-$45K; EMR; insurance; medical-director retainer; working capital) versus $1.5M-$3.5M multi-room flagship (4-8 treatment rooms, CoolSculpting Elite, Morpheus8, fractional CO2, IPL, injector suite, IV bar, GLP-1 program). Expect 6-14 months license-to-doors-open, plus MSO/PC structuring of 60-90 days in CPOM states and medical-director recruiting of 30-90 days.
• Margins: Mature solo med spa runs 55-70% gross and 15-30% net on $1.4M-$3.8M revenue with a mix of 35-45% injectables, 15-25% lasers, 10-20% membership, 10-15% GLP-1 weight loss, and 5-10% retail skincare. Multi-room flagships clear $3.5M-$9M revenue at 18-28% EBITDA. Sale multiples run 5-9x EBITDA single location and 8-12x EBITDA multi-location PE-grade platforms.
• Hardest part: Medical-director recruiting and dependency, state injector scope, good-faith-exam compliance, FDA compounded-GLP-1 enforcement, injector turnover, and Botox price commoditization -- not capital, not concept. CPOM states require an MSO/PC stack and an MD/DO collaborative supervisor; losing the medical director shuts the clinic.
• Per-injector economics: A mature nurse injector generates $400K-$1M in revenue per year and $250K-$700K in contribution margin -- this single unit economic drives every multi-injector, multi-room, and multi-location expansion decision.
• Cross-links: Compare a med spa to the most adjacent regulated cash-pay medical formats -- compounding pharmacy (q9666), mobile IV therapy (q9662), direct primary care (q9660), and pediatric dental (q9668).

1. Foundations: What A Med Spa Is And The Market It Enters

1.1 Defining the med spa and distinguishing it from adjacent formats

A med spa in 2027 is a state-licensed medical aesthetics clinic delivering physician-supervised injectables, energy-based device procedures, medical-grade skincare, and adjunct wellness services in a hybrid retail-clinical environment -- also marketed as a medical spa, aesthetics clinic, cosmetic medical practice, or wellness-plus-aesthetics center.

The defining feature is the medical layer: the procedures performed -- neurotoxin, dermal filler, energy-based skin and body treatments, prescription-strength peels, IV therapy, and weight-loss pharmacotherapy -- require physician involvement, a prescription pathway, and a regulatory structure a non-medical day spa does not have.

The format is best understood by contrast with three adjacent businesses that share patient-facing mechanics but differ in regulation, capital, and unit economics:

This entry centers on the med spa because it occupies the highest-growth, highest-margin medical aesthetics space. It is cash-pay (no insurance-billing friction or payer-mix risk), recurring (membership plus the natural injectable revisit cycle), brand-driven (Instagram, influencer, and retail are the operating reality), and scalable (multi-location, franchise, and private-equity roll-up paths).

The American Med Spa Association (AmSpa), the Medical Spa Society, and IBISWorld classify the med spa as a distinct segment precisely because of this combination -- a medical service business that behaves like a consumer brand.

Each of those four traits cuts both ways. Cash-pay removes the payer cycle, the denied claim, and the 90-120 day receivable, but also removes the insurance buffer that smooths demand: a med spa lives or dies on consumer discretionary spending. Recurring membership revenue is the most powerful margin and valuation lever, but only durable if the operator manages churn.

Brand-driven demand lets a talented operator outcompete a better-capitalized rival, but exposes the business to platform risk and the reality that the brand often lives in an injector's personal Instagram following rather than the clinic's entity. Scalability is real, but scaling multiplies the medical-director, compliance, and injector-recruiting problems rather than diluting them.

The correctly positioned founder understands the med spa as a consumer brand wrapped around a medical practice and respects both halves equally.

1.2 Market size, growth rate, and the 2027 demand reality

The US medical aesthetics segment generates roughly $18B-$22B in annual revenue across approximately 9,200-10,800 active med spas, per AmSpa's State of the Industry report, the Medical Spa Society, and IBISWorld. That segment sits inside the broader $80B-$95B total US aesthetic and cosmetic procedure market documented by the American Society of Plastic Surgeons (ASPS), the Aesthetic Society (ASAPS), and the Allergan Aesthetics 2025 annual report.

It has been compounding at roughly 10-14% annually as injectables crossed from a niche luxury into a mainstream maintenance category and a brand-new channel -- GLP-1 weight loss -- arrived between 2024 and 2027.

Average unit revenue runs $1.4M-$3.8M for a solo clinic and $3.5M-$9M for a multi-room flagship, at 15-30% net for solo operators and 18-28% EBITDA for multi-room formats, per AmSpa, the Cardea Med Spa survey, and RepeatMD operator data. Three structural tailwinds explain the growth: the normalization of preventive ("baby Botox") neurotoxin use among patients in their late twenties and thirties; the maturation of energy-based body contouring (CoolSculpting, Morpheus8, EmSculpt NEO) into mainstream demand; and the GLP-1 weight-loss spike, which added $800-$1,800 per patient per month as a cash channel that barely existed before 2024.

Five things determine survival in years one through three: (1) medical-director relationship discipline -- retainer plus per-procedure economics plus a redundancy plan, because losing the MD shuts the clinic in CPOM states; (2) injector talent strategy -- recruiting, compensating, and retaining nurse injectors; (3) membership penetration -- $99-$299/month recurring memberships reaching 30-50% of mature revenue; (4) GLP-1 and wellness diversification -- Botox-only clinics commoditize fast, so GLP-1, hormone optimization, IV, and skincare retail move margin; and (5) the marketing and reviews engine -- Google reviews at 4.6-plus stars plus Instagram before-and-after content drive 60-80% of new-patient flow.

What is conspicuously absent from that list is telling: not capital, not the treatment menu, not the luxury of the build-out. Every metro has well-capitalized med spas that closed in year two and modest two-room clinics run by a disciplined operator that print money. The five survival factors are relationship and systems problems, not money problems -- a founder can write a check for a Morpheus8 but not for a guarantee that the medical director will not retire or the star injector will not be poached.

Budget capital generously, but spend the founding year's attention on the five factors above.

1.3 The regulatory worldview: three pillars before the doors open

Med spa regulation rests on a three-layer medical-practice stack, and an entrepreneur who treats the med spa as a retail concept will fail the first regulatory review. The three pillars -- state medical-board jurisdiction, the corporate practice of medicine doctrine, and state scope-of-practice rules -- are detailed in Sections 2 and 3.

A med spa is a medical practice that happens to be cash-pay and consumer-branded, and the legal structure must be designed by a healthcare attorney before a lease is signed, equipment ordered, or a patient booked.

2. The Medical-Legal Stack: Medical Director, CPOM, And State Injector Scope

2.1 The medical director requirement

Every state requires a licensed physician (MD or DO) to collaboratively supervise the medical procedures performed at a med spa -- injectables, lasers above esthetician-permitted intensity, IV therapy, and prescription-strength peels. The medical director is not a figurehead: the physician must be in good standing with the state medical board, carry medical malpractice insurance, establish and sign standing orders and clinical protocols, and be reachable for emergencies during operating hours.

Typical compensation runs a $1,500-$3,500 per month retainer plus a per-procedure or per-injector oversight fee ($25-$150 per procedure, or $500-$2,500 per month per injector supervised); in tighter major-metro markets retainers climb to $2,500-$5,000 per month. Some flagship clinics skip the retainer and hire a full-time MD or DO at $180K-$300K plus benefits to consolidate compliance, GFE workflow, and clinical authority under one roof.

Turnkey medical-director platforms -- MedSpa Director Network, MD Telemed, RN Telemed, Empower MD -- source supervising physicians but do not eliminate the dependency risk discussed in the Counter-Case (Section 9).

2.2 The corporate practice of medicine doctrine and the MSO/PC stack

More than 30 states enforce the corporate practice of medicine (CPOM) doctrine, which prohibits a non-physician from owning a medical practice or directly employing physicians. California, New York, Texas, New Jersey, Illinois, Ohio, Michigan, Pennsylvania, Colorado, Arizona, and Massachusetts apply it most strictly.

A non-MD entrepreneur in a CPOM state cannot simply form an LLC, hire a doctor, and open a med spa. The legally compliant solution is the MSO + PC friendly-PC stack:

Healthcare law firms with dedicated aesthetics practices -- Polsinelli, Foley & Lardner, Nelson Mullins, McDermott Will & Emery, ByrdAdatto, Holland & Knight -- typically charge $15K-$45K to structure this stack, draft the MSA, and align it with the state's CPOM interpretation.

This is not optional: a defective MSO/PC stack is grounds for medical-board action, fee-splitting allegations, and an unsellable business. Budget 60-90 days for structuring in a CPOM state.

Two failure modes recur often enough to name. The first is the sham PC: the physician nominally owns the Professional Corporation but exercises no real clinical control and is paid a flat fee that looks like rent for a license. Medical boards and plaintiff attorneys identify these readily, and the consequence is not a fine but the unwinding of the ownership structure and disqualification from sale.

The second is the fee-splitting trap: an MSA tying the management fee to a percentage of clinical revenue in a state that treats that as illegal fee-splitting -- the compliant design uses a fair-market-value management fee supported by an independent valuation. The MSO/PC stack also determines whether the business is sellable at all -- a PE platform buying a med spa in a CPOM state is buying the MSO and assigning the MSA, and a carelessly assembled stack becomes the deal-killer in diligence.

2.3 State injector scope of practice -- who can legally inject

Who is permitted to inject neurotoxin and dermal filler varies dramatically by state, and this single rule reshapes the staffing model, GFE workflow, and labor budget -- a hiring plan built for one state can be illegal in the neighboring one.

The operating rule is permanent: always verify the current state nursing board and medical board rules, because scope of practice changes every one to three years. A regulatory calendar plus a healthcare attorney on retainer is a fixed cost of the business, not a launch expense.

Texas's 2023 tightening and California's 2024 GFE telehealth rule (Section 3.1) show how quickly the ground shifts.

3. Compliance Engine: GFE, HIPAA, EMR, Insurance, And FDA Compounded GLP-1

3.1 The good-faith exam and the post-2024 telehealth tightening

The good-faith exam (GFE) is the regulatory anchor of legal injection. Every patient must have a documented physician (or qualified advanced-practice provider) exam establishing medical appropriateness before any prescription-strength procedure. A compliant GFE includes the chief complaint, relevant medical history, medication reconciliation, allergy review, a physical exam, a treatment plan, and informed consent -- all documented in the EMR.

Historically performed in person by the medical director, the GFE is increasingly delivered via synchronous telehealth video with the medical director or a contracted physician network. The critical 2024 change: asynchronous tele-GFE -- a questionnaire plus photos with no live video -- was used widely 2020-2024, but several states tightened the rule after 2024.

California's AB 2236 now requires synchronous video for an initial GFE, and New York and others moved the same direction. A 2027 GFE workflow must build for synchronous video and treat asynchronous-only GFE as non-compliant in those states.

3.2 HIPAA, EMR, and the med-spa software layer

Med spas are HIPAA-covered entities and must run a HIPAA-compliant EMR with executed business associate agreements, a documented risk assessment, and a photo-release workflow (before-and-after photography is regulated PHI). General-purpose EMRs like Epic and Athenahealth are overkill and optimized for insurance billing; specialty med-spa EMRs are the standard:

3.3 The insurance stack

A med spa carries a medical-grade insurance stack -- medical malpractice is non-negotiable:

3.4 FDA compounded GLP-1 enforcement post-October 2024

The FDA delisted semaglutide from the drug shortage list in October 2024 and entered an active enforcement reset on compounded tirzepatide, materially changing med-spa weight-loss economics in 2025-2027. Off the shortage list, 503A compounding pharmacies are generally restricted from compounding "essentially copies" of the FDA-approved drug (Ozempic, Wegovy, Mounjaro, Zepbound).

Med spas that built GLP-1 programs on compounded semaglutide from 503A pharmacies now face supply disruption, FDA enforcement letters, state pharmacy-board enforcement, and class-action plaintiff risk. Outsourcing Facilities Association litigation is ongoing, so the precise boundary remains in flux.

The compliant workaround paths in 2025-2027:

A med spa building a 2027 weight-loss program must plan a compliant supply path, an MD-stamped clinical protocol, a patient-communication script, and an insurance review for compounded-peptide liability.

The strategic posture matters as much as the legal mechanics. Operators who treated compounded semaglutide as a permanent windfall -- pricing the business around 60-75% margins on a frictionless 503A product -- were the most exposed when the October 2024 delisting changed the rules.

The durable approach treats GLP-1 as a valuable but volatile channel, sizes it as a meaningful contributor but not the foundation of the model, maintains at least two compliant supply paths, and writes patient consent and marketing language conservatively -- never claiming a compounded formulation is equivalent to the branded drug.

4. Real Estate, Build-Out, And The Equipment Stack

4.1 Real estate, suite size, and medical-grade build-out

The real estate and build-out decision is the single biggest capital decision in the launch -- it locks in five to ten years of rent and code compliance. A solo med spa runs 1,500-2,500 sqft (2-4 treatment rooms plus reception, retail wall, injector station, and a small back office); a multi-room flagship runs 3,000-5,000 sqft (5-8 treatment rooms, injector suite, IV bar, laser room, consultation lounge, and a lab).

Rent runs $35-$85 per sqft NNN in metro suburbs, $55-$120 per sqft for urban Class A retail, and $25-$50 per sqft in tertiary markets.

Medical-grade build-out costs $250K-$650K turnkey for a solo clinic (roughly $150-$275 per sqft) and $650K-$1.6M for a flagship. The cost drivers are specifically medical: procedure rooms with hand-wash sinks, lockable Rx storage, medical-grade flooring, HVAC upgraded for laser plume, ADA compliance, NEC electrical for high-amperage laser draws (220V/30A circuits) plus backup power for the IV pump and medical refrigerator, a biohazard waste contract (Stericycle or MedPro Disposal at $150-$400/month), sharps containers, emergency oxygen, an AED, soundproofing, a fire-marshal inspection, and -- where required -- a state Department of Health aesthetic-facility inspection.

Lease structure typically runs a 5-10 year term plus 2-5 year extension options, with 6-12 months of free rent and a $50-$120 per sqft tenant-improvement allowance. A personal guarantee is almost always required for a first-year founder, though a good-guy or burn-down guarantee over three to five years is negotiable.

Three practical lessons separate operators who manage real estate well. First, the medical-grade build-out is slower and more permit-intensive than a retail build-out, routinely running 60-120 days longer than a first-time founder expects, because plan review for hand-wash sinks, dedicated laser circuits, and HVAC plume evacuation involves the building department and sometimes the state Department of Health -- the free-rent period must cover that full window plus a ramp buffer.

Second, the tenant-improvement allowance is real money -- a $75-per-sqft TI allowance on a 2,000 sqft suite is $150,000 of build-out the landlord funds -- and should be negotiated as aggressively as base rent. Third, the site matters more than the rent: a med spa depends on visibility, parking, co-tenancy with complementary traffic, and a demographic match within a three-to-five-mile radius, and a cheap suite in the wrong location permanently caps the appointment book.

4.2 The injectables opening order

Injectables are the revenue engine; the opening order establishes accounts with four manufacturers:

4.3 The energy-based device stack

Equipment is the second-largest capital category, driving the revenue mix for years:

Procedure consumables and small equipment add a chemical-peel inventory of $3K-$8K (SkinCeuticals, ZO, PCA, Obagi), a PRP centrifuge and tubes at $4K-$12K (Eclipse PRP, Selphyl), IV pumps and a hydration-bar build-out at $8K-$25K, and microneedling pens (SkinPen, Dermapen) at $2K-$6K.

Total equipment plus opening injectable inventory runs $150K-$400K for a solo turnkey and $650K-$1.5M for a flagship (3-5 lasers, CoolSculpting, Morpheus8, EmSculpt, the full injectable lineup, an IV bar, and a retail wall).

5. The Capital Stack: Practice Loans, Equipment Finance, And Patient Financing

5.1 How a med spa is financed

Med spa capital stacks are dominated by practice loans, equipment finance, and founder equity on the cost side, with patient financing on the revenue side. Founder equity runs $75K-$400K -- higher than a food truck or fitness studio because the medical build-out and equipment require meaningful skin in the game -- often funded by physician-partner equity, operator savings, or a 401(k) ROBS rollover.

Practice loans of $500K-$1.5M (solo) or $2M-$5M+ (flagship) come from specialist medical-practice lenders -- Live Oak Bank is the largest dental/medical SBA lender -- at Prime + 2.0-4.5% over 7-10 years with 15-25% down. SBA 7(a) loans of $500K-$5M fund a practice purchase plus build-out at an 8-12% effective rate over ten years, though some lenders restrict cosmetic-only practices.

Equipment finance of $100K-$800K covers lasers, CoolSculpting, Morpheus8, and EmSculpt at an 8-15% effective rate over five to seven years, often via the manufacturer's in-house program.

5.2 Patient financing -- the revenue-side multiplier

Patient financing is not optional in modern med spa; it converts a $5K-$10K treatment plan into a closeable sale. Carecredit (Synchrony) dominates the med-spa, dental, and veterinary space, financing $1K-$25K procedures at a promotional 0% APR over 6-24 months while the clinic pays a 5-15% merchant discount rate.

Cherry is the modern alternative ($200-$10K, faster underwriting, 0-29.99% APR, 3.9-10% MDR); Affirm and Klarna cover retail and lower-ticket purchases, Alphaeon Credit (Comenity/Bread) is specialty-aesthetic, and GreenSky handles larger packages. At mature clinics, 15-35% of revenue runs through patient financing.

A typical solo turnkey capital stack lands at $400K-$1.5M (25-35% equity, 45-55% practice/SBA loan, 15-25% equipment finance, plus a LOC); a flagship runs $1.5M-$3.5M (20-30% equity, 50-60% practice loan, 20-30% equipment finance, plus a LOC).

6. Operations: Staffing, Tech Stack, And Membership Models

6.1 The staffing model and per-injector economics

Staffing is the largest operating line after rent and drug cost, and the medical-director and injector decisions drive both medical-legal viability and the revenue ceiling.

The nurse injector is the single biggest revenue lever in the clinic. The unit economic that matters: a mature nurse injector generates $1,800-$4,500 per day in revenue (15-30 patients across a mix of toxin, filler, and laser hair removal). At 220 working days a year that is $400K-$1M in revenue per injector, and with an all-in injector cost around $130K plus commission and benefits, a productive injector clears $250K-$700K in contribution margin per year.

This number is the engine behind every multi-injector and multi-room expansion.

Because the injector is so central, staffing strategy deserves more than a compensation table. The recruiting market is adversarial -- demand outpaces supply three to five times over in major metros -- so a founder competes not only on base pay but on pre-booked patients, a manageable schedule, modern equipment, marketing support for the injector's personal brand, paid CME, and a culture that does not burn people out.

Compensation shapes behavior: a pure-commission injector may resist sharing patients, while a base-plus-commission structure with a team component aligns the injector with the clinic. Retention is the harder half -- because injector relationships and followings are portable and non-compete enforcement is weak, the practical defenses are equity or profit-share for senior injectors, a clinic brand strong enough to hold patient loyalty, and spreading patient relationships across the team.

The most dangerous posture is one injector controlling 60-80% of revenue with no reason to stay. The healthiest multi-injector clinics cap any single injector's revenue share, build a junior-injector training pipeline early, and treat the second and third hires as risk management as much as growth.

6.2 The technology stack -- EMR, booking, and payments

The tech stack is the difference between a 30% net clinic and a 12% net clinic. EMR options are detailed in Section 3.2 -- Aesthetic Record, Boulevard, Symplast, AestheticsPro, RepeatMD, Nextech -- and booking can also run through Zenoti, Mindbody, or Vagaro. Payment processing runs through Square (single-location, 2.6% + 10 cents), Stripe (custom, e-commerce, and membership billing), and the patient-financing rails (Carecredit, Cherry, Affirm, Klarna).

6.3 Membership models and the loyalty layer

$99-$299 per month recurring memberships are the single most important financial discipline in a modern med spa. Mature membership penetration of 25-45% of active patients translates into 30-50% of mature revenue arriving as recurring cash. Typical tiers:

On top of clinic memberships sit the manufacturer loyalty programs -- Allergan's Allē, Galderma's ASPIRE, and Revance's RHA Rewards -- which bank patient points and lift retention 15-30% when patients enroll at the first visit. Retail skincare (SkinCeuticals, ZO, Obagi, SkinMedica, Alastin, Revision, Colorescience) adds 5-12% of mature revenue and creates between-visit touchpoints.

Membership earns the label "single most important financial discipline" because it transforms the business three ways at once. First, it converts unpredictable, marketing-dependent demand into a contracted recurring base: 300 members at an average $175 per month is roughly $630,000 of annual revenue that arrives regardless of the month's marketing.

Second, it raises lifetime value -- a member visits more often, buys more retail, and adds higher-margin treatments. Third, membership penetration is the single biggest driver of the exit multiple: a buyer underwrites recurring contracted revenue at a higher multiple, so two clinics with identical EBITDA can trade at different valuations on membership mix alone.

The corollary, covered in the Counter-Case, is that a membership is only an asset if churn is actively managed -- a base bleeding 6% a month is a treadmill, not a moat.

7. Pricing, Revenue Mix, And GLP-1 Economics

7.1 Per-procedure pricing and the revenue mix

Per-procedure pricing separates a 22% net clinic from a 9% net clinic -- small price increases plus injector productivity drive disproportionate margin gains. The mature solo revenue mix runs 35-45% injectables, 15-25% lasers, 10-20% membership, 10-15% GLP-1/wellness, and 5-10% retail skincare.

A typical neurotoxin treatment runs 20-50 units across the forehead, glabellar, and crow's-feet areas, producing a $240-$900 session at $12-$18 per unit, with the patient returning every three to four months (longer with Daxxify, a premium $16-$22 per unit for its six-month duration). Dermal filler treatments use one to three syringes per visit.

7.2 GLP-1 weight-loss economics

The GLP-1 weight-loss program is the 2024-2027 revenue spike, running $800-$1,800 per patient per month across a monthly prescription, a monthly office visit, a B12 add-on, and clinical management. Branded Wegovy or Zepbound (via LillyDirect or NovoCare) is compliance-clean but compresses margin to 25-50%; compounded 503A formulations run 60-75% gross margin but carry the FDA enforcement risk in Section 3.4.

A mature 150-500 active-patient program is a $1.4M-$10.8M annual revenue channel. Adjacent wellness lines round out the mix: IV hydration and NAD+ ($125-$350 per IV bag, $650-$2,000 per NAD+ infusion), B12 and lipotropic shots ($25-$60), and hormone optimization ($200-$450 per month including labs and Rx).

7.3 Marketing -- the patient-acquisition engine

Marketing in 2027 med spa runs roughly 40-55% Instagram, 15-25% Google reviews, 10-20% referral, 10-15% paid digital, and 5-10% events and community.

Instagram before-and-after content is the single highest-leverage marketing activity. Daily grid posts and Reels showing toxin, filler, Morpheus8, and CoolSculpting results -- with patient consent and a HIPAA-compliant photo release -- drive organic flow once a clinic clears the 5K-50K follower threshold, and top injector personal accounts (15K-200K followers) drive 30-60% of new-patient flow at injector-led brands.

Google Business Profile reviews -- 50-300 at 4.6-plus stars, automated via Birdeye, Podium, NiceJob, or Weave -- are the search-decisive threshold, because med spa patients read 20-50 reviews before booking.

The deeper marketing question is one of moat. The corporate chains -- LaserAway, Ideal Image, Skin Laundry, Ever/Body -- outspend any independent on paid digital by one to two orders of magnitude, so competing for share-of-voice on Google and Meta auctions is a losing game. The independent's defensible position is the opposite of national scale: hyper-local trust and a recognizable human face -- a named injector with a visible track record, detailed five-star reviews from the same zip code, referrals, and content showing real results on real patients.

That is why the marketing mix tilts toward owned and earned channels. The practical risk is platform dependence: if 50% of new patients come from one injector's personal Instagram, the clinic does not own its demand. The mature answer is to build the clinic's own branded account in parallel, feature multiple injectors, convert social followers into an owned email and SMS list via Klaviyo, and treat the referral program and review engine as the most durable parts of the acquisition system.

8. Growth And Exit: Franchise, Multi-Location, And PE Roll-Up

8.1 Franchise versus independent

The corporate and franchise landscape now competes directly with independents in nearly every major metro. LaserAway (corporate, 150+ locations, backed by Hg Capital and previously Bain Capital) and Ideal Image (150+ locations, L Catterton and Sentinel Capital) run national volume models and undercut independents with $9-$12-per-unit Botox.

Sona Dermatology + Med Spa (40+ locations, Southeast) runs a combined derm and med-spa model. Hand & Stone (500+ franchise locations, $400K-$700K investment, 6.5% royalty) adds light aesthetic services. Skin Laundry (premium laser-facial chain, 40+ locations, MidOcean Partners) runs a subscription model.

Restore Hyper Wellness (220+ locations, $700K-$1.5M investment, 7-9% royalty) is wellness-centric and adding injectables and GLP-1. Ever/Body (NYC tri-state premium, 15+ locations, General Atlantic and Norwest) is the premium-brand benchmark.

Franchise economics run a $400K-$1.5M initial investment plus a 6-9% royalty plus a 1-3% marketing fund. The pros are brand recognition, training, national advertising, and supplier discounts; the cons are royalty drag, territory restrictions, and reduced customization. Most successful independent operators avoid franchise and build their own brand, because royalty margin compression is severe in a cash-pay aesthetic business.

8.2 The multi-location playbook

The growth path from a solo location to a multi-location regional brand follows defined stages with capital and management triggers:

Stage 3 -- the second location in the same metro -- requires a central GM, a traveling injector, and shared back-office and marketing, and its Year 1-2 ramp temporarily drags blended margin. Stage 4 (3-6 locations with central admin, injector training, and shared inventory) becomes a regional platform attractive to private equity.

Stage 5 is a PE recapitalization or strategic sale at 8-12x EBITDA, with the founder typically rolling 20-40% equity and staying as platform CEO for three to five years.

8.3 PE roll-up 2023-2027 and exit comps

Private equity activity in medical aesthetics and dermatology surged 2023-2027 as sponsors recognized cash-pay, recurring, scalable, recession-resilient unit economics. Active platforms include U.S. Dermatology Partners (ABRY Partners), Forefront Dermatology (OMERS, Partners Group, FFL Partners historically), Schweiger Dermatology Group (Harvest Partners, AEA Investors), and Advanced Dermatology & Cosmetic Surgery / ADCS (Harvest Partners, Audax).

The most active roll-up sponsors are Audax, Genstar, Harvest Partners, Hildred Capital Management, FFL Partners, Comvest, NMS Capital, NewSpring, and BPOC.

To maximize the eventual exit, a founder should make years-one-through-three decisions with the diligence checklist already in mind. A quality-of-earnings review scrutinizes exactly what a first-time owner treats casually: a clean MSO/PC structure, documented medical-director oversight, a low-churn membership base with contracted recurring revenue, financials that separate owner compensation from true cash flow, and an acquisition system not dependent on one departing injector's personal brand.

A clinic operated from day one as a sellable asset commands the top of its multiple range; one dressed up at the last minute discovers a deal-value gap six and seven figures wide. The exit is the cumulative product of three to seven years of operating discipline, not a separate phase.

9. Counter-Case: When A Med Spa Is A Bad Bet And When The Plan Fails

A serious founder must stress-test the case above against the conditions that make this category a difficult bet in 2027. The 14-element counter-case follows.

9.1 Medical-director, scope, and FDA risks

(1) Medical-director recruiting and dependency. In CPOM states (CA, NY, TX, NJ, IL, OH, MI, PA, CO, AZ, MA), losing the medical director shuts the clinic immediately. The supervising-physician market is tight and price-rising ($2,500-$5,000 per month retainer in major metros), and many MDs supervise three to eight clinics, so divided attention is the norm.

Backup MD relationships and a dual-supervisor structure are essential but rare. MD turnover -- death, retirement, a scope dispute, a board complaint -- is the single largest single-point-of-failure risk in a CPOM-state med spa.

(2) Nurse-injector poaching wars and commission inflation. The aesthetic-injector market is dramatically short-staffed -- demand outpaces supply three to five times over in major metros. Signing bonuses of $10K-$50K plus a $90K-$160K base plus 10-25% commission plus paid CME are baseline, and LaserAway, Ideal Image, and Ever/Body poach top injectors aggressively.

Year 1-3 injector turnover of 40-70% per year is the baseline, and top injectors take their patient book with them because the Instagram following is portable. Non-compete enforcement is weak -- losing your top injector can drop revenue 20-50% overnight.

(3) Botox commoditization and corporate pricing undercut. LaserAway and Ideal Image pricing at $9-$12 per unit has compressed the independent-clinic Botox band from $14-$18 in 2019 to $12-$16 in 2027. Daxxify ($16-$22 per unit, six-month duration) is a partial premium-tier defense, but most patients shop on price.

Independents in competitive metros face 2-4% annual toxin margin compression without offsetting growth in fillers, lasers, and GLP-1.

(4) FDA compounded GLP-1 enforcement post-October 2024. The FDA delisted semaglutide in October 2024 and reset tirzepatide enforcement, with ongoing litigation. Med spas that built weight-loss programs on compounded peptides from 503A pharmacies face enforcement letters, state pharmacy-board action, and class-action exposure.

Branded Wegovy or Zepbound is compliance-clean but squeezes margin to 25-50% versus 60-75% compounded. Operators need an MD-stamped protocol, an insurance review, updated consent, and a supply-backup plan.

(5) State injector scope tightening and GFE telehealth restrictions. California's AB 2236 (2024) requires synchronous video for an initial GFE, making the asynchronous questionnaire-plus-photo GFE used 2020-2024 non-compliant there. Texas tightened its delegation protocol in 2023, New Jersey restricts injection to APNs, and New York and Massachusetts are trending tighter.

Future legislative and medical-board activity is a permanent compliance overhead -- operators need a regulatory calendar, a state-by-state compliance log, and a healthcare attorney on retainer.

9.2 Cost, capital, and equipment risks

(6) OBBBA, tax, and depreciation policy changes. The One Big Beautiful Bill Act of 2025 affects bonus depreciation and Section 179 expensing on lasers, CoolSculpting, Morpheus8, and EmSculpt; depreciation-policy changes can shift effective device economics 5-15% over a five-to-seven-year ownership cycle.

State sales-tax-on-aesthetic-services pushes in Connecticut, Minnesota, and Washington would add 6.35-10.4% sales tax to currently-untaxed cosmetic procedures -- a real margin event for affected operators.

(7) Real estate and build-out cost inflation 2020-2027. Medical-grade build-out cost rose 40-65% from 2020 to 2027, driven by HVAC, electrical, plumbing, sink and biohazard code, and labor shortage. Solo turnkey now runs $400K-$1.5M versus $250K-$700K pre-pandemic, and lease rates in medical-suburban and Class A retail are up 25-50% in major metros.

Operators signing 2025-2027 leases must build a higher fixed-cost base into the unit economics, raising the breakeven revenue floor $150K-$400K per year versus a 2019 baseline.

(8) Equipment obsolescence, maintenance, and warranty drag. Laser, RF, CoolSculpting, and Morpheus8 equipment has a five-to-eight-year useful life plus $5K-$25K per year per device in maintenance and extended warranty, and next-generation devices create patient-pull pressure to upgrade every three to five years.

An operator with $500K-$2M in 3-5 lasers faces a perpetual reinvestment cycle and genuine obsolescence risk.

9.3 Clinical, brand, and consolidation risks

(9) Injector and patient injury exposure plus malpractice premium pressure. Filler vascular occlusion (necrosis, rarely blindness), laser burns, chemical-peel scarring, and GLP-1 adverse events are the highest-frequency lawsuit categories, and aesthetic-specialty malpractice premiums rose 20-40% from 2020 to 2027.

A single serious adverse event can drive a $500K-$5M-plus settlement plus premium re-rating and reputation damage even with comprehensive insurance. A clinical protocol, on-hand hyaluronidase, emergency-response training, photo documentation, and consent forms are non-negotiable.

(10) Brand commoditization and corporate marketing scale. LaserAway, Ideal Image, Skin Laundry, and Ever/Body each spend $5M-$50M per year on national Meta, Google, and influencer marketing -- an independent with a $3K-$15K per month budget cannot compete on share-of-voice. Differentiation through injector personality, Instagram, community, and concierge experience is the only sustainable independent moat, and it requires owner-operator personal-brand investment many founders are not prepared for.

(11) Membership churn and GLP-1 patient transience. $99-$299 per month memberships churn at 4-8% per month -- 50-70% annualized -- without active retention discipline. GLP-1 patients are notoriously transient, many cycling out at 6-12 months once a weight goal is approached. Operators need continuous patient acquisition, membership engagement, and maintenance-dose protocols to sustain run-rate revenue.

(12) Photo-release and HIPAA breach exposure. Before-and-after photo marketing is the Instagram lifeblood, but HIPAA-compliant photo release, storage, transmission, and revocation is a regulatory minefield. One photo posted without proper consent can drive HHS HIPAA enforcement of $1.5K-$1.5M per incident plus a civil suit and reputational damage.

Cyber liability insurance, a photo-release template, and an EMR-integrated consent workflow are essential.

(13) Staff burnout and clinical fatigue. Injectors work six-to-eight-hour service days back-to-back -- physically demanding (hand, shoulder, neck strain) and mentally demanding (precision plus patient-anxiety management). Patient coordinators face high-pressure commission-tied conversion targets, and multi-location GM staff face 60-80 hour weeks.

The 40-70% Year 1-3 staff turnover drives recruiting cost, service-quality degradation, and patient defection.

(14) PE roll-up consolidation pressure. The 2023-2027 PE roll-up has compressed regional independents between corporate national chains undercutting on price and PE-backed regional platforms outspending on marketing and recruiting. Independents in active-roll-up metros face margin compression, injector poaching, and recruiting cost inflation.

The options become: sell into a platform at 5-9x EBITDA; become a multi-location platform with capital and a management bench; or carve a defensible premium niche. Staying solo and competitive in a PE-consolidated metro is the hardest path.

Honest verdict. The med spa remains a viable, high-margin entrepreneurial path in 2027 if the founder can honestly check most of the following: a reliable medical director plus a documented backup and a healthcare attorney on retainer for CPOM and MSO/PC compliance; a nurse-injector recruiting and retention framework that treats injectors as the single biggest revenue lever; 25-45% membership penetration as the cash-flow stabilizer; a GLP-1 supply path built on compliant branded Rx, defensible compounding, a clinical protocol, and a supply backup; Instagram, Google reviews, and referral as the marketing reality with $3K-$15K per month in paid digital; medical-director risk, injector turnover, commoditization, FDA enforcement, GFE tightening, build-out inflation, equipment obsolescence, malpractice, and PE consolidation treated as model line items rather than surprises; a clear commitment to either the lifestyle solo path (15-30% net) or the multi-location PE-exit path (8-12x EBITDA); and an honest assessment of capital, management bench, and a 60-80 hour-per-week founder commitment before signing a $500K-$1.5M practice loan.

A founder who cannot check most of those will find the economics of 2027 medical aesthetics grind the clinic toward a Year 2-3 distressed sale at 3-5x SDE or worse.

10. Benchmarks And Five-Year Trajectory

10.1 Industry size and unit-economic benchmarks

10.2 Five-year cash-flow trajectory: solo med spa

10.3 Reading the trajectory honestly

The five-year trajectory above is the median-success path, not a promise. Year 1 is deliberately thin -- a 5-15% net margin reflects build-out amortization, the medical-director retainer, insurance, and the first injectors all running while the appointment book fills. The inflection happens in Year 2 as membership climbs and marketing compounds, and again in Year 3 as a second injector and a GLP-1 program add revenue without proportionally adding fixed cost.

The most common way the trajectory breaks is an over-leveraged Year 1: a $1.4M build-out at the top of the range, a high-rate equipment stack, and a thin working-capital cushion leave no margin for a slow ramp, and debt service alone can convert a recoverable slow start into a distressed sale.

The disciplined version keeps Year 1 fixed costs as low as code allows, raises a working-capital cushion sized to 9-12 months of operating expense, and treats the second location as a Year 3-4 decision funded partly by the first clinic's cash flow.

11. Frequently Asked Questions

How much does it cost to open a med spa in 2027? A solo turnkey med spa (1,500-2,500 sqft, 2-4 rooms) runs $400K-$1.5M all-in -- $250K-$650K medical build-out, $30K-$80K opening Allergan injectables order, $85K-$250K per laser, plus EMR, insurance, the medical-director retainer, and working capital.

A multi-room flagship (3,000-5,000 sqft) runs $1.5M-$3.5M.

Do I need to be a doctor to own a med spa? Not necessarily, but in the 30-plus CPOM states a non-physician owner must use an MSO + Professional Corporation "friendly-PC" stack -- a licensed physician owns the PC, the entrepreneur owns the management company. A healthcare law firm structures this for $15K-$45K.

Can a registered nurse inject Botox? It depends on the state. California, Florida, New York, Arizona, and Nevada permit RN injection under MD delegation and a standing order following the good-faith exam; New Jersey restricts injection to APNs, PAs, and physicians only. Always verify current state nursing-board and medical-board rules before building the staffing model.

How long does it take to open? Plan for 6-14 months from licensing to doors open, plus 60-90 days for MSO/PC structuring in a CPOM state and 30-90 days for medical-director recruiting.

What is the most profitable service? Body-contouring devices (Morpheus8, CoolSculpting) carry the highest per-procedure gross margins at 70-86%, but injectables drive 35-45% of revenue and are the volume engine. Membership revenue carries the best margin profile at 70-85% and stabilizes cash flow.

Is the GLP-1 weight-loss revenue durable? It is a real channel ($800-$1,800 per patient per month, $1.4M-$10.8M annually for a 150-500 patient program), but it carries FDA compounded-drug enforcement risk post-October-2024 and patient transience -- many cycle out at 6-12 months.

Build it on a compliant supply path with a clinical protocol, and do not let it become the whole business.

What is the hardest part of running a med spa? Not capital and not concept -- it is medical-director dependency, nurse-injector recruiting and turnover (40-70% per year), state injector-scope compliance, FDA compounded-GLP-1 enforcement, and Botox price commoditization by corporate chains.

What can I sell the business for? A profitable single-location med spa with $400K-$1.5M EBITDA and a strong injectables-plus-membership mix sells at 5-9x EBITDA to a local PE-backed platform; a multi-location regional brand sells at 8-12x EBITDA; premium urban brands reach 12-18x EBITDA.

Related Pulse Entries

• (q9666) -- How do you start a compounding pharmacy business in 2027? The most direct sibling: 503A/503B compounding, FDA enforcement, and the GLP-1 supply chain that feeds med spa weight-loss programs.
• (q9662) -- How do you start a mobile IV therapy clinic in 2027? A close sibling: state-regulated medical service, IV therapy, GLP-1, and a cash-pay model with medical-director supervision.
• (q9660) -- How do you start a direct primary care (DPC / concierge medicine) practice in 2027? A sibling on the cash-pay, recurring-membership, physician-led medical-practice model.
• (q9668) -- How do you start a pediatric dental practice in 2027? A sibling state-licensed clinical practice that combines cash-pay and insurance revenue with a medical build-out.
• (q9659) -- How do you start a medical spa (med spa) business in 2027? The earlier baseline of this same topic; this entry (q9671) is the 2027 deep refresh.
• (q9665) -- How do you start a boutique fitness studio business in 2027? A sibling on the $99-$299/month recurring-membership model and customer-experience-driven retention.
• (q9661) -- How do you start a veterinary clinic in 2027? A sibling specialty-licensed practice with cash-pay revenue, equipment intensity, and PE roll-up dynamics.

Sources

1. AmSpa American Med Spa Association (americanmedspa.org) -- Largest US med spa trade association; annual State of the Industry report, legal and compliance resources, medical-director directory. https://www.americanmedspa.org
2. AmSpa State Legal Summaries (americanmedspa.org/legal) -- State-by-state med spa legal and regulatory summaries. https://www.americanmedspa.org/page/legal
3. Medical Spa Society (medicalspasociety.org) -- Trade association serving med spa operators and clinical staff. https://www.medicalspasociety.org
4. American Society of Plastic Surgeons / ASPS (plasticsurgery.org) -- Annual aesthetic and cosmetic procedure statistics and clinical guidelines. https://www.plasticsurgery.org
5. Aesthetic Society / ASAPS (theaestheticsociety.org) -- Annual Aesthetic Procedure Statistics and aesthetic-surgeon trade body. https://www.theaestheticsociety.org
6. American Society for Dermatologic Surgery / ASDS (asds.net) -- Dermatologic surgery procedure survey and clinical-practice guidance. https://www.asds.net
7. IBISWorld Medical Spas Industry Report (ibisworld.com) -- US medical spa industry market size, growth, and operating-ratio benchmarks. https://www.ibisworld.com
8. FDA Drug Shortages and Compounded Drug Determinations (fda.gov) -- FDA shortage-list determinations and 503A compounding enforcement for semaglutide and tirzepatide. https://www.fda.gov/drugs/drug-shortages
9. FDA Human Drug Compounding 503A and 503B Framework (fda.gov) -- FDA framework for traditional 503A and outsourcing 503B compounding pharmacies. https://www.fda.gov/drugs/human-drug-compounding
10. HHS HIPAA Privacy and Security Rule (hhs.gov/hipaa) -- Federal HIPAA framework for covered entities including med spas handling PHI. https://www.hhs.gov/hipaa
11. DEA Drug Enforcement Administration Registration (deadiversion.usdoj.gov) -- DEA practitioner registration for controlled-substance dispensing. https://www.deadiversion.usdoj.gov
12. California Board of Registered Nursing Scope of Practice (rn.ca.gov) -- CA RN scope of practice including aesthetic injection under MD delegation and standing order. https://www.rn.ca.gov
13. California Medical Board Corporate Practice of Medicine (mbc.ca.gov) -- CA Medical Board CPOM doctrine and medical-practice ownership rules. https://www.mbc.ca.gov
14. California AB 2236 Good Faith Exam Telehealth (leginfo.legislature.ca.gov) -- CA legislation requiring synchronous video for an initial GFE in aesthetic medicine. https://leginfo.legislature.ca.gov
15. New York State Education Department Office of the Professions (op.nysed.gov) -- NY scope of practice for RN, NP, and PA in medical aesthetics. http://www.op.nysed.gov
16. Texas Medical Board Non-Surgical Medical Cosmetic Procedures (tmb.state.tx.us) -- TX rules on aesthetic-injection delegation and the 2023 tightening. https://www.tmb.state.tx.us
17. Florida Department of Health Medical Quality Assurance (floridahealth.gov) -- FL medical-board oversight including aesthetic medicine. http://www.floridahealth.gov
18. New Jersey State Board of Nursing / Advanced Practice (njconsumeraffairs.gov) -- NJ APN-only scope for aesthetic injection. https://www.njconsumeraffairs.gov/nur
19. Allergan Aesthetics 2025 Annual Report (allergan.com) -- Allergan Aesthetics (AbbVie) annual financial and product data including Botox and Juvederm. https://www.allergan.com
20. Galderma 2025 Annual Report (galderma.com) -- Galderma annual report including Restylane, Dysport, and Sculptra data. https://www.galderma.com
21. Revance Therapeutics Annual Report (revance.com) -- Revance, Daxxify long-acting toxin, and the RHA Collection filler line. https://www.revance.com
22. Merz Pharma (merz.com) -- Merz Xeomin, Belotero, and Radiesse aesthetic portfolio. https://www.merz.com
23. AbbVie Aesthetics Practice Financing (allerganaestheticsdirect.com) -- Allergan/AbbVie equipment and injectable opening-order financing. https://www.allerganaestheticsdirect.com
24. InMode Annual Report (inmodemd.com) -- InMode Morpheus8, BodyTite, and Forma equipment platforms. https://inmodemd.com
25. BTL Aesthetics (btlaesthetics.com) -- BTL EmSculpt NEO, Emsella, and Vanquish device data. https://www.btlaesthetics.com
26. Candela Medical (candelamedical.com) -- Candela GentleMax Pro, GentleLase Pro, and PicoWay laser platforms. https://www.candelamedical.com
27. Cynosure (cynosure.com) -- Cynosure Elite iQ, PicoSure Pro, and SmartSkin+ device platforms. https://www.cynosure.com
28. Cutera (cutera.com) -- Cutera excel V+, truSculpt, and AviClear platforms. https://www.cutera.com
29. Sciton (sciton.com) -- Sciton Joule, BBL HERO, ProFractional, and Erbium platforms. https://www.sciton.com
30. Lumenis (lumenis.com) -- Lumenis UltraPulse CO2 and IPL platforms. https://www.lumenis.com
31. HydraFacial / Beauty Health Company (beautyhealth.com) -- HydraFacial machine, Syndeo, and Boost serum platform. https://www.beautyhealth.com
32. CoolSculpting Elite by Allergan/AbbVie (coolsculpting.com) -- CoolSculpting Elite dual-applicator cryolipolysis platform. https://www.coolsculpting.com
33. Eli Lilly LillyDirect for Zepbound (lillydirect.com) -- Direct pharmacy and telehealth pathway for branded tirzepatide. https://www.lillydirect.com
34. Novo Nordisk NovoCare for Wegovy and Ozempic (novocare.com) -- Direct pharmacy and savings pathway for branded semaglutide. https://www.novocare.com
35. Empower Pharmacy (empowerpharmacy.com) -- Major 503A and 503B compounding pharmacy serving aesthetics and wellness. https://www.empowerpharmacy.com
36. Aesthetic Record EMR (aestheticrecord.com) -- Leading dedicated med-spa EMR, booking, and photo management. https://www.aestheticrecord.com
37. Boulevard Salon and Med Spa Software (joinblvd.com) -- Modern med-spa EMR, booking, membership, and retail platform. https://www.joinblvd.com
38. RepeatMD (repeatmd.com) -- Med-spa membership, loyalty, and e-commerce upsell engine layered on the EMR; operator benchmark data. https://www.repeatmd.com
39. Allergan Allē Loyalty Program (alle.com) -- Allergan patient loyalty program banking points across Botox, Juvederm, and CoolSculpting. https://www.alle.com
40. Galderma ASPIRE Rewards (aspirerewards.com) -- Galderma patient loyalty program for Dysport, Restylane, and Sculptra. https://www.aspirerewards.com
41. Carecredit Patient Financing (carecredit.com) -- Synchrony-backed patient financing dominant in dental, aesthetic, and veterinary. https://www.carecredit.com
42. Cherry Patient Financing (withcherry.com) -- Modern patient-financing platform ($200-$10K) with faster underwriting. https://www.withcherry.com
43. Live Oak Bank Practice Solutions (liveoakbank.com) -- Largest dental and medical-practice SBA and commercial lender. https://www.liveoakbank.com
44. Bank of America Practice Solutions (bankofamerica.com) -- BofA dedicated medical and dental practice lending. https://www.bankofamerica.com/smallbusiness/practice-solutions/
45. Polsinelli Healthcare Law (polsinelli.com) -- Healthcare law firm structuring MSO/PC stacks for med spas. https://www.polsinelli.com
46. ByrdAdatto Healthcare Law (byrdadatto.com) -- Dedicated medical-aesthetics and healthcare law firm. https://byrdadatto.com
47. Coverys Medical Professional Liability (coverys.com) -- Medical malpractice carrier for physicians and APPs. https://www.coverys.com
48. Stericycle Medical and Biohazard Waste (stericycle.com) -- Medical waste, biohazard, and sharps disposal contracts. https://www.stericycle.com
49. Schweiger Dermatology Group (schweigerderm.com) -- Northeast dermatology and med-spa platform backed by Harvest Partners and AEA Investors. https://www.schweigerderm.com
50. U.S. Dermatology Partners (usdermatologypartners.com) -- National dermatology and medical-aesthetics platform backed by ABRY Partners. https://www.usdermatologypartners.com
51. Cardea Med Spa Industry Survey (cardea.com) -- Med spa operator survey on revenue mix, margin, and unit economics. https://www.cardea.com
52. Outsourcing Facilities Association (508a.org) -- Trade body for 503B outsourcing facilities; party to compounded-GLP-1 litigation. https://www.508a.org